Company intelligence / Profile preview

Suzhou Kebo Ruijun Biosciences

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Suzhou Kebo Ruijun Biosciences is a joint venture focused on the development of innovative immuno-oncology therapies. Its lead program is JS019, a recombinant fully human anti-CD39 monoclonal antibody currently in Phase 1 clinical trials for advanced solid tumors and lymphomas. The company has received regulatory approval to conduct these trials in China[2][3][1]. No clinical efficacy data have been published as of June 2025.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyRecombinant protein
Industry: Biotech

Partnerships

Beijing Eirene Biotech Co., Ltd. (joint venture partner)[2][3]

Beyond the preview

Go deeper on Suzhou Kebo Ruijun Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Kebo Ruijun Biosciences.